Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from rHuEPO to intravenous darbepoetin alfa in haemodialysis patients with CKD-related anemia
2004-004499-35Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2005
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of darbepoetin alfa in anaemia (2 arms), sponsored by Amgen. Started Jan 2005; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anaemia
Beyond the preview
Go deeper on 2004-004499-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004499-35.